The study population includes all patients aged over 18 with a neuroendocrine tumor grade I and II and a clinical indication for PRRT.
Conditions
Brief summary
The absorbed dose in target lesions measured on SPECT/CT imaging
Detailed description
The absorbed dose in normal tissue (kidneys, liver, spleen) measured on SPECT/CT imaging, The bone marrow dose is determined using blood withdrawals and SPECT/CT imaging, The uptake on SPECT/CT between target lesions and the liver and spleen measured on the 24 hours’ time point, The effect of continued LA-SSA use on specific population pharmacokinetic parameters will be qualified using population pharmacokinetic modelling using the acquired SPECT/CT scans and blood samples for dosimetry
Interventions
Sponsors
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The absorbed dose in target lesions measured on SPECT/CT imaging | — |
Secondary
| Measure | Time frame |
|---|---|
| The absorbed dose in normal tissue (kidneys, liver, spleen) measured on SPECT/CT imaging, The bone marrow dose is determined using blood withdrawals and SPECT/CT imaging, The uptake on SPECT/CT between target lesions and the liver and spleen measured on the 24 hours’ time point, The effect of continued LA-SSA use on specific population pharmacokinetic parameters will be qualified using population pharmacokinetic modelling using the acquired SPECT/CT scans and blood samples for dosimetry | — |
Countries
Netherlands
Outcome results
None listed